A silent health crisis is gradually tightening its grip, thriving where clean water, basic sanitation and timely medical care are missing.
Doctors in wealthy countries rarely see it, yet this age‑old infection keeps mutating in crowded cities and rural villages, steadily outsmarting the very drugs meant to control it.
An old killer that never really went away
Typhoid fever sounds like a disease from a Victorian novel, something conquered long ago with sewers and soap. That impression is dangerously misleading. The infection, caused by the bacterium Salmonella enterica serovar Typhi (usually shortened to Salmonella Typhi), still infects an estimated 9–15 million people every year and kills more than 100,000, mostly in Asia and sub‑Saharan Africa.
Historical records suggest typhoid has stalked humans for thousands of years. Some historians believe it may even have contributed to the death of Alexander the Great. As drinking water, sewage systems and vaccination programmes improved in Europe and North America during the 20th century, cases there plunged. The disease never vanished though; it simply retreated to places where infrastructure and healthcare budgets are thin.
Typhoid is often described by researchers as a “disease of inequality”: it flourishes where pipes, vaccines and laboratories are missing.
In those settings, antibiotics became the main line of defence from the 1950s onwards. For a while, they worked remarkably well. Then the bacteria adapted.
How typhoid keeps dodging antibiotics
The story of typhoid treatment is also a story of resistance, replayed with each new generation of drugs. When chloramphenicol was introduced in the late 1940s, it transformed care for typhoid fever and dramatically reduced deaths. Within just a couple of years, resistant strains were being reported.
That pattern repeated itself. Ampicillin, cotrimoxazole and later the fluoroquinolones were all hailed as breakthroughs. Each time, Salmonella Typhi evolved ways to survive. Genetic studies now show that certain highly successful lineages, particularly a group known as haplotype H58, have spread widely and carry multiple resistance genes.
Researchers recently analysed more than 7,500 bacterial samples from patients with typhoid collected between 1905 and 2019 across dozens of countries. Their sequencing work revealed that resistant strains do not just appear and then disappear. They persist, move across borders and gradually displace more susceptible strains, especially where antibiotics are heavily used and poorly regulated.
In parts of South Asia, the bacteria behind typhoid now shrug off nearly every common oral antibiotic that used to cure the disease.
➡️ A total solar eclipse will be visible again in France (and we know the date)
➡️ A South African giraffe with a strange neck baffles scientists
➡️ They Are Under 60 And Already Living With Alzheimer’s
The rise of XDR typhoid
The most worrying form is known as XDR typhoid, short for “extensively drug‑resistant” typhoid. Since around 2016, one such strain has dominated outbreaks in Pakistan. It resists at least five major classes of antibiotics, including many older drugs and commonly used fluoroquinolones.
At the moment, only a handful of treatments still work reliably. Among oral options, azithromycin is often the last practical choice in many settings. For severe cases, some injectable, hospital‑based drugs can still be used, but they are expensive and difficult to roll out at scale in poorer regions.
Genetic mutations first detected in Bangladesh in 2013 are now chipping away at azithromycin’s effectiveness too. They alter a gene called acrB, which affects how the drug is pumped out of the bacterial cell. Those changes have so far been found mainly in non‑XDR strains, but experts warn that if these resistance traits combine with XDR lineages, truly untreatable typhoid could emerge.
When a “tropical disease” goes global
Typhoid is often labelled as a disease of South Asia or parts of Africa, yet resistant strains no longer respect those boundaries. Studies from international surveillance groups show that since the 1990s, drug‑resistant typhoid has been detected on every continent.
Most confirmed cases in Europe and North America still occur in people who recently travelled to high‑incidence countries or visited family there. But those travel‑linked infections act as a bridge, giving resistant strains opportunities to move into new environments. International migration, medical tourism and humanitarian crises all add further pathways for spread.
Airlines can move a resistant strain from Karachi to London in less time than it takes the patient’s symptoms to fully develop.
This creates a dangerous illusion for wealthier countries. While typhoid remains rare at home, their citizens are connected to parts of the world where the disease is becoming harder and harder to treat. Hospitals must now check travel histories carefully and use more complex antibiotic combinations for returning travellers with a persistent fever.
A disease shaped by inequality
The geography of typhoid has always tracked infrastructure. Where tap water is safe and sewage is treated, the disease loses its main transmission routes. Where people rely on contaminated rivers, crowded latrines or informal water vendors, the bacteria find easy access to new hosts.
In many low‑income areas, antibiotics became the cheapest workaround. With limited lab diagnostics, health workers often prescribe them “just in case” for any prolonged fever. Unregulated pharmacies and informal drug sellers make it easy to buy pills without a test or prescription. That combination is perfect for encouraging resistance.
- Unsafe drinking water and poor sanitation fuel transmission
- Overuse of antibiotics drives the evolution of resistant strains
- Weak surveillance systems delay detection of new variants
- Limited vaccination coverage leaves huge populations vulnerable
Communities with the least political power often face the highest exposure. Children, who are more likely to ingest contaminated water and have weaker immune defences, carry a large share of the disease burden.
Vaccines give hope, but not a free pass
In the last decade, a new generation of typhoid conjugate vaccines (TCVs) has offered a more durable shield. Unlike older vaccines that required multiple doses and did not work well in younger children, TCVs can be given from around six months of age and provide longer‑lasting protection.
One widely used TCV, Typbar‑TCV®, was developed in India and has shown strong performance in real‑world campaigns. During an outbreak in the Pakistani city of Hyderabad, data suggested around 97% effectiveness even against XDR strains, a striking result in such a difficult setting.
Countries that introduce typhoid conjugate vaccines are not just cutting cases – they are also reducing the number of infections that might evolve into resistant strains.
Global health agencies now recommend routine TCV use in countries where typhoid is common, alongside targeted catch‑up campaigns for older children. Yet vaccine rollout has been uneven. Some governments struggle with cost, logistics or competing health priorities such as Covid‑19 recovery and measles surges.
Why vaccines alone won’t solve resistance
Vaccination reduces the number of people who fall ill, which in turn cuts antibiotic use. That slows the evolution of resistance, but does not stop it completely. As long as contaminated water and poor sanitation keep seeding outbreaks, and as long as antibiotics are easily available without proper guidance, typhoid will keep finding ways to adapt.
Experts often describe an “ABC” strategy for typhoid: Antibiotics used wisely, Better infrastructure for water and sanitation, and Childhood vaccination. Miss one of those pillars and the others carry more pressure than they can sustain.
What antibiotic resistance actually means for patients
For people living in countries like the UK or US, antibiotic resistance can sound abstract. Typhoid makes those consequences very tangible. A drug‑susceptible infection might respond to a short course of pills, allowing a child to return to school in a week or two. A resistant infection can mean weeks in hospital, intravenous drugs, serious complications, or permanent disability from intestinal damage.
| Type of typhoid infection | Typical treatment | Practical impact |
|---|---|---|
| Drug‑susceptible | Standard oral antibiotics | Short illness, limited hospital time, lower cost |
| Multi‑drug resistant | Newer, more expensive drugs | Longer fever, higher costs, more side effects |
| XDR typhoid | Few remaining options, often injections | Prolonged hospital stay, greater risk of complications and death |
For health systems already stretched thin, a surge in resistant typhoid cases means more beds occupied, higher drug bills and less capacity for other conditions such as childbirth, trauma or cancer care.
What could happen if resistance keeps rising
Public‑health researchers have modelled future scenarios. If current trends in resistance continue and vaccine rollout stalls, large cities in South Asia and parts of Africa could face more frequent and harder‑to‑control outbreaks. Seasonal peaks during monsoon rains or flooding events might bring thousands of severe cases at once.
In a worst‑case scenario where azithromycin resistance merges with XDR typhoid and spreads widely, doctors would increasingly rely on last‑line injected drugs such as carbapenems. Those are costly and need hospital care. Many rural clinics simply do not have them. That would leave countless patients with few realistic options, especially during humanitarian emergencies.
Countries with low incidence would not be spared. Imported cases of near‑untreatable typhoid would raise the stakes for infection‑control teams, much like drug‑resistant tuberculosis has done. Standard advice for travellers – “don’t drink the tap water, peel your fruit” – would suddenly matter even more.
How individuals and governments can reduce the risk
For governments in high‑burden regions, three actions repeatedly surface in expert recommendations: expand access to TCVs, invest in clean water and sewerage, and regulate antibiotic sales more tightly. None are quick wins, but together they address the roots of both disease and resistance.
For people travelling to affected areas, basic steps still make a difference: getting vaccinated if eligible, being cautious with food and water, and seeking medical advice early if a high fever and stomach pain appear after a trip. Mentioning recent travel to a doctor can speed up proper testing, which reduces the temptation to hand out broad‑spectrum antibiotics “just in case”.
The typhoid story also offers a broader warning. Bacteria do not respect borders, and resistance can turn once‑curable infections into serious threats again. Paying attention to an “old” disease now may prevent far more difficult battles in future, not only against typhoid but against a long list of common infections that are starting to follow the same path.
Originally posted 2026-02-06 16:00:17.